Kornimate/medical-research-clean huggingface dataset:
physical activity and recreation school program for special needs individuals and their parents

Conditions: Adolescent Behavior; Children, Only; Child Behavior Problem

Summary: the general purpose of this project; "physical activity and recreation school" for the evaluation of physical activity behaviors of individuals with physical disabilities between the ages of 6-18, to increase the level of knowledge and awareness of these individuals and their parents, and to enable individuals with special needs to experience sports activities in the company of health and sports professionals who are experts in their fields. is to arrange. this project consists of three main topics as evaluation, training and experimentation. during the evaluation phase, interactive roundtable activity, valid and reliable scales and physical assessments, and barriers and motivators for physical activity participation of individuals with special needs will be evaluated. a comprehensive interactive training seminar on physical activity will be held for individuals with special needs and parents during the training phase. in the experimentation phase, children and adolescents with special needs will participate in training programs that include exercise and sportive activities suitable for the determined physical activity barriers and motivators, and will have the opportunity to experience exercises and sportive activities that they have not experienced before. the results of this project will provide gains in the analysis and application of physical inactivity, which is seen as an important public health problem in our country, for individuals with special needs, and will also guide many relevant institutions, health professionals and educators.


Eligibility criteria:
inclusion criteria: for individuals with special needs; * between the ages of 6-18 * being diagnosed with cerebral palsy, neuromuscular muscle disease, spina bifida or having a chronic neurological or orthopedic problem that causes physical disability * being in a wheelchair/ able to walk with an assistive device or independently * have a cognitive level to understand and communicate questions * being residing in the province of istanbul for parents of individuals with special needs; * being the mother or father of a special needs child or adolescent * volunteering for a special needs child to participate in the study * being able to participate in the activities to be held within the scope of the project on a full-time basis * have a cognitive level to understand and communicate questions * using a smart phone. exclusion criteria: for individuals with special needs; * having a cognitive problem that will prevent the application of the evaluation parameters * failure to approve the assessment by the custodial parent * having had lower extremity surgery in the last 6 months * doing regular physical activity in the last 6 months * being a professional athlete for parents of individuals with special needs; * being illiterate. * not living with a special needs child.

Keywords: physical inactivity physical disability adolescent behavior children, only child behavior problem
postprandial response to almond consumption in overweight hispanic pregnant women

Conditions: Diabetes, Gestational

Summary: currently, about one third of all women entering pregnancy are obese. the prevalence of metabolic disorders during pregnancy has increased concurrently with the rise in maternal obesity. although dietary interventions are used routinely to reduce metabolic disease in non-pregnant obese individuals, no specific dietary advice is provided to obese, pregnant women unless they develop gestational diabetes mellitus. in this study, the investigators will specifically assess the effect of replacing dairy fats with almonds in a breakfast meal on the postprandial metabolic response. this cross-over, randomized control trial will examine the postprandial metabolic response to 0 or 2 oz of almonds in standardized test meals in pregnant hispanic women with prepregnancy bmi between 25 and 40. hispanics are at higher risk for gestational diabetes and the metabolic syndrome. the investigators hypothesize that consuming almonds in place of dairy fat reduces the glycemic response and improves the postprandial lipid profile in these high-risk women.


Eligibility criteria:
inclusion criteria: * pregnant hispanic women * between 30 and 36 weeks gestation * prepregnancy bmi between 25 and 40 exclusion criteria: * diagnosis of gestational diabetes mellitus * preexisting diabetes mellitus * renal disease * thyroid disease * cardiovascular disease * history of drug abuse * nut allergies

Keywords: postprandial insulin resistance lipids satiety almonds
doxorubicin hydrochloride liposome in treating women with ductal carcinoma in situ undergoing surgery

Conditions: Breast Cancer

Summary: rationale: drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. purpose: this clinical trial is studying the side effects of doxorubicin hydrochloride liposome and to see how well it works in treating women with ductal carcinoma in situ undergoing surgery.

objectives: * to demonstrate the efficacy and safety of neoadjuvant intraductal pegylated liposomal doxorubicin hydrochloride in women with ductal breast carcinoma in situ undergoing surgery. * to demonstrate the ability to identify and cannulate the duct demonstrating precancerous disease in these women. * to integrate the humboldt community breast health project into the planning and execution of this study. outline: patients undergo identification of the intraductal lesions via cannulization. patients receive pegylated liposomal doxorubicin hydrochloride (pld) intraductally through the inserted cannula. some patients are randomized to receive saline instead of pld. within 4-6 weeks, all patients undergo surgery. patients undergo tissue and ductal fluid sample collection at baseline and at surgery for correlative laboratory studies. tissue samples are assessed for histomorphology, proliferation (ki67), cell death (apoptosis index), genetic markers, necrosis, inflammation, and loss of heterozygosity by he stain, ihc, tunel, and pcr. nipple aspirate and ductal lavage fluid samples are analyzed for cytomorphology (cellular atypia), proliferation (ki67), cell death (tunel), differentiation (g-actin), and genetic markers (fish) by quantitative fluorescence image analysis. samples are also analyzed for bfgf and cea by elisa, and methylation by pcr. after completion of study therapy, patients are followed every 6 months for at least 2 years.

Eligibility criteria:
disease characteristics: * diagnosis of ductal breast carcinoma in situ by core needle biopsy * no pathological invasive or microinvasive disease in the affected breast * mammographic microcalcifications are limited to one ductal system or one quadrant of breast * hormone receptor status not specified patient characteristics: * menopausal status not specified * must be able to undergo necessary surgery * not pregnant prior concurrent therapy: * no prior surgery or radiotherapy to the recently diagnosed breast * more than 12 months since prior chemotherapy * no prior subareolar breast surgery to the affected breast * not concurrently involved in a research protocol for unapproved new drug evaluation

Keywords: ductal breast carcinoma in situ
development of an online program to help manage chronic pain in children and teenagers

Conditions: Chronic Pain

Summary: this research seeks to develop an internet-based program to help teenagers manage pain at home using a variety of techniques from physiotherapy, medicine, psychology and nursing. this study uses interviews to investigate what content and features teenagers and their parents want to see in an online intervention for managing chronic pain in teenagers.

this research seeks to develop an internet-based programme to help teenagers manage pain at home using a variety of techniques that mirror clinical practice. this includes content from medicine, physiotherapy, nursing and psychological techniques, such as relaxation. the study will use interviews (one semi-structured interview and one 'think-aloud' interview per participant) to explore the question: what content and features do young people with chronic pain, and their parents want to see in an online pain management intervention? the study seeks to recruit a group of teenagers from great ormond street hospital, as well as a group of parents. after the first round of interviews, participants have the option to be contacted about the second round. recruitment for the first round of interviews will continue up until the point where no additional insights are found by adding new data to the analysis ('point of saturation'). we anticipate 30 teenagers and 30 parents will be sufficient. we hope to recruit young people with a mixture of ages and sexes, as well as a mixture of different pain diagnoses, and parents with varying backgrounds and sexes where possible. the insights gathered from this study will help develop a new program for managing chronic pain in teenagers, which we aim to make available through the nhs. the internet-based intervention hopes to contribute to successful chronic pain management at home, and may be used as an adjunct to clinical services, such as the pain control service at great ormond street hospital.

Eligibility criteria:
inclusion criteria: * adolescents aged 12 to 17 years * adolescents experiencing chronic pain of any type (minimum duration of three months). * parents or legal guardians of adolescents, aged 12 to 17 years, who are experiencing chronic pain of any type (minimum duration of three months). exclusion criteria: * unable to communicate in fluent, spoken english. * adolescents aged 18 years or over. * adolescents with chronic cancer pain that are continuing to undergo treatments to eradicate their primary cancer or have received these treatments in the last three months (maintenance therapies are acceptable).

Keywords: chronic pain paediatric pain pain management qualitative research
randomized controlled trial of intranasal ketamine vs. intranasal midazolam in individuals with ocd

Conditions: Obsessive-Compulsive Disorder

Summary: obsessive-compulsive disorder (ocd) is a common illness that causes significant distress and impairment. currently, serotonin reuptake inhibitors (sris) are the only medications that are fda-approved to treat ocd. unfortunately, sris can take a long time to work (2-3 months), and even then they usually only partially reduce ocd symptoms. the present study, will test if intranasal ketamine is feasible to use and can reduce ocd symptoms significantly more than a comparison medication called midazolam. therefore, you may or may not receive ketamine as part of this study. results from this study will allow doctors and researchers to better understand if you and others with ocd may respond to this class of medications.


Eligibility criteria:
inclusion criteria: * age 18-55 * physically healthy and not currently pregnant * primary diagnosis of ocd * sufficient severity of symptoms * for all patients on medications, medications dose must be stable for at least 6 weeks prior to enrollment. must discuss with dr. current medications and doses. * able to provide consent exclusion criteria: * first degree relative with schizophrenia * psychiatric conditions that would make participation unsafe determined by study doctor * female patients who are either pregnant or nursing * planning to start ex/rp during the period of the study or those who have completed an adequate dose of ex/rp (defined as 8 or more sessions within 2 months) within 8 weeks prior to enrollment. * nasal obstruction or history of nasal surgery * currently on psychotropic medication or other medication likely to interact with the glutamate system * medical conditions that make participation unsafe * allergy or intolerance to ketamine or midazolam

Keywords: ocd
collagen-targeted pet imaging for early interstitial lung disease

Conditions: Interstitial Lung Disease

Summary: the goal of this study is to investigate the ability of \[68ga\]cbp8 to detect collagen deposition in early interstitial lung disease.

\[68ga\]cbp8, is a pet imaging probe which selectively binds collagen type i. collagen deposition is a pivotal event in the development of pulmonary fibrosis. \[68ga\]cbp8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. \[68ga\]cbp8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. in addition, \[68ga\]cbp8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis. the goals of this study are: 1. to determine whether collagen deposition as assessed by \[68ga\]cbp8-pet mri can detect increased collagen deposition in early interstitial lung disease and 2. if the degree of \[68ga\]cbp8 uptake predicts subsequent disease progression.

Eligibility criteria:
inclusion criteria: group 1: first degree relatives of a family member with pulmonary fibrosis (n=8) * age greater than 40 years * have the ability to give written informed consent * first degree relative of a family member with pulmonary fibrosis * no known history of interstitial lung disease * no tobacco use within the prior 6 months. group 2: subjects with interstitial lung abnormalities (ilas) or interstitial lung disease (ild) (n=22) * age greater than 40 years * have the ability to give written informed consent * ilas or early ild (defined by presence of reticular markings and / or traction bronchiectasis but absence of a definite uip pattern) * no tobacco use within the prior 6 months. exclusion criteria: * electrical implants such as cardiac pacemaker or perfusion pump * ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, or steel implants ferromagnetic objects such as jewelry or metal clips in clothing * historical egfr of less than 30 ml/min/1.73 m2 * pregnant or breastfeeding (a negative quantitative serum hcg pregnancy test is required for females having child-bearing potential before the subject can participate) * claustrophobic reactions * research-related radiation exposure exceeds current radiology department guidelines (i.e. 50 msv in the prior 12 months) * unable to lie comfortably on a bed inside the mr-pet * bmi \> 33 (limit of the pet-mri table) * determined by the investigator(s) to be clinically unsuitable for the study (e.g. based on screening visit and/or during study procedures) * pneumonia or other acute respiratory illness within 6 weeks of study entry * parenchymal lung disease except for ild/ilas or emphysema * acute exacerbation of ild within the prior 6 months * vats within the prior 6 months * prior radiation therapy to the thorax * known allergy to gadolinium.
evaluation of an intensive education program on the treatment of tobacco use disorder for pharmacists: a randomized controlled trial

Conditions: Smoking Cessation

Summary: in qatar, tobacco use is one of the main causes of premature deaths and preventable diseases. as per the 2013 global adult tobacco survey (gats), 12.1% of adults and 20.2% of men in qatar smoke tobacco, and 55.4% of this smoke an average of 16 cigarettes or more per day. moreover, 15.7% of school students aged 13 to 15 years currently use some form of tobacco according to the 2013 global youth tobacco survey (gyts). in qatar, tobacco-related diseases including cardiovascular diseases and cancers are highly prevalent. in an effort to reduce tobacco use, qatar has ratified the who framework convention on tobacco control (fctc) and has implemented many tobacco control initiatives. in spite of these measures, tobacco use is still rising in qatar. pharmacists practicing in retail/community pharmacy are often the first port of call for individuals requiring health advice in general. evidence has proven that they have a pivotal role in health promotion and disease prevention including tobacco cessation. hence, pharmacists have excellent opportunities to reduce tobacco use in qatar. yet, ambulatory and community pharmacists in qatar are not sufficiently contributing to tobacco control. based on published data, only 21% of community pharmacists in qatar always or most of the time ask patients about their smoking status. furthermore, when asked about their smoking cessation training, 89% of pharmacists did not receive any kind of education or training about smoking cessation counseling in the past. in an effort to build the capacity of pharmacists in qatar, the aim of the proposed study is to design, implement and evaluate an intensive education program on tobacco treatment for pharmacists in qatar. the study will be a prospective randomized controlled trial comparing the effectiveness of the education program on pharmacists' tobacco cessation-related knowledge, attitudes, self-efficacy, and skills.


Eligibility criteria:
inclusion criteria: * retail/community pharmacists practicing in qatar will be eligible for participation in the study. exclusion criteria: * none
a randomized, controlled, unblinded, clinical trial of the acceptability and efficacy of non-pharmaceutical methods in preventing spread of influenza within the family

Conditions: Influenza

Summary: the proposed study will evaluate whether the use of non-pharmaceutical methods, such as surgical masks, isolation of patients and personal hygiene, are acceptable and effective in preventing the spread of influenza within the family.this will be achieved by conducting a randomized, controlled, unblinded, clinical trial. family members of an index case with influenza like illness, will be randomly allocated to two groups. in the intervention group, family members will receive comprehensive guidance about sanitation and hygiene, as well as surgical masks to wear whenever in close contact (3 feet / 1 meter) with the index case. in addition, they will be asked to isolate the index case as much as possible. in the control group, family members will receive only standard guidance about sanitation and hygiene relevant for reducing the transmission of influenza. the primary end-point of the study will be secondary infection of influenza of at least one of the family members in order to asses the efficacy of the interventions. in addition, the compliance to those interventions will be evaluated. the study hypothesis is that use of non-pharmaceutical methods will be acceptable and will reduce the secondary infection rate among them by 50%.


Eligibility criteria:
inclusion criteria: * family members of an index case with influenza-like illness (ili) during the first two days of his illness. * no limitations will be given regarding the number of family members. exclusion criteria: * presence of another household member with ili during the previous two weeks.
treatment of type i hepatorenal syndrome (hrs) with pentoxyfylline

Conditions: Hepatorenal Syndrome

Summary: pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of type i hepatorenal syndrome in the first 14 days of hospitalization.

each hospitalized subject will undergo pre-dosing screening with review of his or her history and physical exam from the day of enrollment and safety assessment to ensure no contraindication to use of ptx. type i hrs will be defined according to the criteria put forth by the american association for the study of liver disease as (1) cirrhosis with ascites; (2) serum creatinine greater than 1.5 mg/dl; (3) no improvement of serum creatinine (decrease to a level of 1.5 mg/dl or less) after at least two days with diuretic withdrawal and volume expansion with albumin; (4) absence of shock; (5) no current or recent treatment with nephrotoxic drugs; and (6) absence of parenchymal kidney disease as indicated by proteinuria \>500 mg/day, microhematuria (\>50 red blood cells per high power field), and/or abnormal renal ultrasonography. baseline testing will be obtained from hospitalization records, including but not limited to chemistry panel, liver function testing, urinalysis, urine electrolytes, coagulation studies, blood cultures, chest x-ray, diagnostic paracentesis, abdominal ultrasound with doppler. subjects will take either placebo three times a day or pentoxyfylline 400mg three times a day or 400mg twice a day for egfr 10-50 and 400mg once a day for egfr \<10 for 90 days in addition to standard amo therapy. treatment will be continued for 14 days unless a study endpoint has been reached at which time either ptx or placebo will be stopped

Eligibility criteria:
inclusion criteria: * hospitalized patients with acute or chronic liver disease * type i hrs * aged greater than or equal to 18 * non-pregnant exclusion criteria: * allergy or hypersensitivity to ptx or intolerance to methylxanthines (e.g. caffeine, theophylline) * concurrent use of nephrotoxic drugs * age less than 18 * pregnancy * uncontrolled bacterial infection * renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease, interstitial nephritis and urinary obstruction) * shock * tnf alpha antagonist use * subject is institutionalized or a prisoner * recent cerebral or retinal hemorrhage (contraindication to ptx) * severe or poorly controlled cardiovascular disease as determined by the principal investigator to hinder the ability to adhere to study protocols

Keywords: hepatorenal syndrome renal failure pentoxyfylline liver transplantation cirrhosis
the optimal treatment for treatment-resistant schizophrenia

Conditions: Schizophrenia

Summary: the optimal treatment for treatment-resistant schizophrenia

to explore the curative effect and safety of risperidone，aripiprazole，sodium valproate，modified electroconvulsive therapy(mect), or magnetic seizure therapy(mst) with clozapine in the treatment of treatment-resistant schizophrenia， and to provide the basis for clinical medication.

Eligibility criteria:
inclusion criteria: * the diagnosis of schizophrenia according to dsm-v * 18～60 years old * 2 prior failed treatment trials with 2 different antipsychotics at doses of at least 600 mg/day chlorpromazine equivalents, each of at least 6 weeks duration; * signed an informed consent exclusion criteria: * patients to be diagnosed according to dsm-v for substance abused, development delayed * suffering from serious physical disease and can not accept the treatment * mst contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure * allergic to risperidone ,aripiprazole, or sodium valproate * participated in any clinical subject within 30 days * pregnancy or lactation

Keywords: schizophrenia